|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013216,
umls-concept:C0027976,
umls-concept:C0030705,
umls-concept:C0146224,
umls-concept:C0332293,
umls-concept:C0441655,
umls-concept:C0574032,
umls-concept:C0851347,
umls-concept:C1140680,
umls-concept:C1512288,
umls-concept:C1514162
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2000-1-6
|
|
pubmed:abstractText |
Twenty-one-day topotecan infusion was administered as second-line therapy in patients with previously treated ovarian cancer (based on our prior favorable phase I experience) to determine its activity, time to progression, and pharmacodynamics.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2553-61
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:10561322-Adult,
pubmed-meshheading:10561322-Aged,
pubmed-meshheading:10561322-Aged, 80 and over,
pubmed-meshheading:10561322-Antineoplastic Agents,
pubmed-meshheading:10561322-Area Under Curve,
pubmed-meshheading:10561322-Cisplatin,
pubmed-meshheading:10561322-Female,
pubmed-meshheading:10561322-Humans,
pubmed-meshheading:10561322-Infusions, Intravenous,
pubmed-meshheading:10561322-Middle Aged,
pubmed-meshheading:10561322-Ovarian Neoplasms,
pubmed-meshheading:10561322-Topotecan,
pubmed-meshheading:10561322-Treatment Outcome
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group.
|
|
pubmed:affiliation |
Kaplan Cancer Center and New York University Medical Center, New York, and Albert Einstein College of Medicine, Bronx, NY, USA. howard.hochster@med.nyu.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
